Homozygous and HeterozygousCCR5-Δ32Genotypes Are Associated ... : JAIDS Journal of Acquired Immune Deficiency Syndromes (original) (raw)

Articles: PDF Only

Homozygous and Heterozygous CCR5-Δ32 Genotypes Are Associated With Resistance to HIV Infection

Marmor, Michael*; Sheppard, Haynes W.†; Donnell, Deborah‡; Bozeman, Sam§; Celum, Connie∥

Susan Buchbinder, #Beryl Koblin, and §**George R. Seage III for the HIV Network for Prevention Trials Vaccine Preparedness Protocol Team

*_Departments of Environmental Medicine and Medicine, New York University School of Medicine, New York, New York;†_Viral and Rickettsial Disease Laboratory, Division of Communicable Disease Control, California Department of Health Services, Berkeley, California; ‡Fred Hutchinson Cancer Research Center, Seattle, Washington; §Abt Associates, Cambridge, Massachusetts; ∥Department of Medicine, University of Washington, Seattle, Washington; ¶San Francisco Department of Public Health, San Francisco, California; #New York Blood Center, New York, New York; and **Department of Epidemiology, Harvard University School of Public Health, Boston, Massachusetts, U.S.A.

Address correspondence and reprint requests to Michael Marmor, Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, 5th Floor, New York, NY 10016-3240, U.S.A.; e-mail: [email protected] Manuscript received December 18, 2000; accepted May 30, 2001.

Abstract

Objective:

To investigate evidence for resistance to HIV-1 infection associated with the heterozygous genotype CCR5-+/Δ32 and with the homozygous genotype _CCR5_- Δ32/Δ32, which results in a nonfunctional CCR5 receptor.

Design:

Cohort study of initially HIV-seronegative high-risk individuals from eight different cities. Enrollment data were analyzed to investigate the association of demographic factors and risk behaviors with CCR5 genotypes on the assumption that increased genotype prevalence among persons with histories of longer or more intensive exposure to HIV would indicate HIV resistance associated with that genotype. Longitudinal data were analyzed to investigate the association of HIV seroincidence with CCR5 genotypes. The cohort of 2996 individuals included 1892 men who have sex with men (MSM), 474 male injection drug users (IDUs), 347 women at heterosexual risk, and 283 female IDUs.

Measurements:

CCR5 genotype, HIV serostatus, demographic factors, and risk behaviors during the 6 months before enrollment, followed by measurement of HIV seroincidence during the subsequent 18 months (for men) and 24 months (for women).

Results:

Forty (1.3%) subjects were homozygous CCR5-Δ32/Δ32 and 387 (12.9%) were heterozygous CCR5-+/Δ32. All but 1 CCR5-Δ32/Δ32 individuals and 51 _CCR5_- +/Δ32 individuals were Caucasian. Among 1531 Caucasian MSM, _CCR5-+/_Δ32 individuals were present more frequently (22.3%) among those reporting unprotected receptive anal intercourse than among those not reporting this risk (15.9%) (p = .002), suggesting a selective advantage of the heterozygous genotype. CCR5-+/Δ32 individuals also had a significantly reduced relative risk of HIV seroconversion adjusted for unprotected receptive anal intercourse compared with CCR5-+/+ individuals (relative risk = 0.30, 95% confidence interval [CI]: 0.08-0.97). _CCR5_-Δ32/Δ32 prevalence among Caucasian MSM was significantly associated with age among subjects recruited from high HIV seroprevalence cities (New York City and San Francisco) (odds ratio [OR] for each decade increase in age = 2.57, CI: 1.56-4.21) but not among those recruited from lower HIV prevalence sites (Boston, Chicago, Philadelphia, Seattle, and Providence/Pawtucket, Rhode Island) (OR = 1.20, CI: 0.75-1.89).

Conclusions:

Cross-sectional and longitudinal analyses indicated that among high-risk HIV seronegative MSM, CCR5-+/Δ32 and _CCR5_-Δ32/Δ32 are associated with protection against HIV infection. These findings imply that strategies aimed at reducing susceptibility to HIV infection by blocking CCR5 receptor sites need not seek blockage of all receptor sites to achieve an imperfect but substantial degree of protection.

© 2001 Lippincott Williams & Wilkins, Inc.

Full Text Access for Subscribers:

Not a Subscriber?